Two novel TB drugs move into human studies

(MENAFN- The Maravi Post) By Shobha Shukla, CNS (Citizen News Service) (CNS): On the eve of the 48th Union World conference on Lung Health, being held in Guadalajara, Mexico, the Global Alliance for TB Drug Development (TB Alliance) announced the ongoing Phase-1 clinical studies for two new drugs for TB treatment, developed by it. Both compounds have proceeded through […]" /> img.wp-smiley, img.emoji { display: inline !important; border: none !important; box-shadow: none !important; height: 1em !important; width: 1em !important; margin: 0 .07em !important; vertical-align: -0.1em !important; background: none !important; padding: 0 !important; } .sfsi_plus_subscribe_Popinner { width: 100% !important; height: auto !important; border: 1px solid #b5b5b5 !important; padding: 18px 0px !important; background-color: #ffffff !important; } .sfsi_plus_subscribe_Popinner form { margin: 0 20px !important; } .sfsi_plus_subscribe_Popinner h5 { font-family: Helvetica,Arial,sans-serif !important; font-weight: bold !important; color: #000000 !important; font-size: 16px !important; text-align: center !important; margin: 0 0 10px !important; padding: 0 !important; } .sfsi_plus_subscription_form_field { margin: 5px 0 !important; width: 100% !important; display: inline-flex; display: -webkit-inline-flex; } .sfsi_plus_subscription_form_field input { width: 100% !important; padding: 10px 0px !important; } .sfsi_plus_subscribe_Popinner input[type=email] { font-family: Helvetica,Arial,sans-serif !important; font-style: normal !important; color: !important; font-size: 14px !important; text-align: center !important; } .sfsi_plus_subscribe_Popinner input[type=email]::-webkit-input-placeholder { font-family: Helvetica,Arial,sans-serif !important; font-style: normal !important; color: !important; font-size: 14px !important; text-align: center !important; } .sfsi_plus_subscribe_Popinner input[type=email]:-moz-placeholder { /* Firefox 18- */ font-family: Helvetica,Arial,sans-serif !important; font-style: normal !important; color: !important; font-size: 14px !important; text-align: center !important; } .sfsi_plus_subscribe_Popinner input[type=email]::-moz-placeholder { /* Firefox 19+ */ font-family: Helvetica,Arial,sans-serif !important; font-style: normal !important; color: !important; font-size: 14px !important; text-align: center !important; } .sfsi_plus_subscribe_Popinner input[type=email]:-ms-input-placeholder { font-family: Helvetica,Arial,sans-serif !important; font-style: normal !important; color: !important; font-size: 14px !important; text-align: center !important; } .sfsi_plus_subscribe_Popinner input[type=submit] { font-family: Helvetica,Arial,sans-serif !important; font-weight: bold !important; color: #000000 !important; font-size: 16px !important; text-align: center !important; background-color: #dedede !important; } /* Body color changing option */ body { background: ; } /* Global Color Scheme */ /* Post Title Color */ .posttitle h2 a, #title h3 a, #title h3 { color: ; } /* Content Color */ .cotent-text, .posttextcontent p, #content p, body, .zc a, #thearchivelist a { color: ; } /*Block #3*/ .featured-category-title a{ color: ; } .slider-title{ background-color: ; } .section-two-cat-title a{ color: ; } .section1-category a{ color: ; } .section2-category a{ color: ; } .section3-category a{ color: ; } .section4-category a{ color: ; } /* Heading Color */ { color: ; } /* H1 to h6*/ h1, h2, h3, h4, h5, h6 { color: ; } /* Sidebar Title Color */ .sidebar-widget-title span{ color: #dd3333; } /* Block colors */ .block-1 .category-title {border-color: #00c13a; } .block-1 .cat-block-meta a {color: #00c13a; } .block-2 .category-title {border-color: ; } .block-2 .cat-block-meta a {color: ; } .block-3 .category-title {border-color: ; } .block-3 .cat-block-meta a {color: ; } .block-4 .category-title {border-color: ; } .block-5 .category-title {border-color: ; } .block-6 .category-title {border-color: ; } .block-7 .category-title {border-color: ; } .block-8 .category-title {border-color: ; } .block-9 .category-title {border-color: ; } .si_captcha_small { width:175px; height:45px; padding-top:10px; padding-bottom:10px; } .si_captcha_large { width:250px; height:60px; padding-top:10px; padding-bottom:10px; } img#si_image_com { border-style:none; margin:0; padding-right:5px; float:left; } img#si_image_reg { border-style:none; margin:0; padding-right:5px; float:left; } img#si_image_log { border-style:none; margin:0; padding-right:5px; float:left; } img#si_image_side_login { border-style:none; margin:0; padding-right:5px; float:left; } img#si_image_checkout { border-style:none; margin:0; padding-right:5px; float:left; } img#si_image_jetpack { border-style:none; margin:0; padding-right:5px; float:left; } img#si_image_bbpress_topic { border-style:none; margin:0; padding-right:5px; float:left; } .si_captcha_refresh { border-style:none; margin:0; vertical-align:bottom; } div#si_captcha_input { display:block; padding-top:15px; padding-bottom:5px; } label#si_captcha_code_label { margin:0; } input#si_captcha_code_input { width:65px; } p#si_captcha_code_p { clear: left; padding-top:10px; } .si-captcha-jetpack-error { color:#DC3232; }

By Shobha Shukla, CNS (Citizen News Service)

(CNS): On the eve of the 48th Union World Conference on Lung Health, being held in Guadalajara, Mexico, the Global Alliance for TB Drug Development (TB Alliance) announced the ongoing Phase-1 clinical studies for two new drugs for TB treatment, developed by it.

Both compounds have proceeded through early pre-clinical development and were granted "Investigative New Drug" status by the US Food and Drug Administration.

TBA-7371 and Sutezolid are the two new additions to the sparse pipeline of new antibiotics against a disease that not only kills 1.8 million people every year, but is also becoming increasingly resistant to the older drugs. With resistance to current TB treatments continuously growing, the need for compounds with no pre-existing resistance increases. That is why these two drugs entering human studies give great hope.

TBA-7371 is an antimicrobial compound that belongs to a novel class of drugs known as DprE1 inhibitors, of which there are two other compounds in early development. Its mechanism of action is cell wall disruption. With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB. Phase-1 study for this began in August 2017.

Sutezolid, whose phase-1 study started in September 2017, is an oxazolidinone - a class of drugs that has already shown evidence of clinical activity against TB. The oxazolidinone, linezolid, has shown promising results as part of the Nix-TB study testing a treatment for extensively drug-resistant TB (XDR-TB). However, the toxicity associated with long term administration of linezolid can be problematic.

TB Alliance and the Medicines Patent Pool have already announced a sub licensing agreement for the development and commercialization of sutezolid for the treatment of TB.

It would be pertinent to mention here that two other TB treatment regimens put forward by TB Alliance: Nix-TB study comprising BPaL regimen (Bedaquiline, Pretomanid, Linezolid and Pyrazinamide) to treat XDR-TB and and N-005 study comprising BPaMZ regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin, Pyrazinamide) to treat drug sensitive as well as drug resistant TB - are in advanced stages of clinical studies and have shown very promising results to simplify and improve TB treatment for all forms of TB.

"While we still have a way to go before we arrive at a universal cure for this disease, we have building blocks coming through the research pipeline that show us we can get there," said Dr Mel Spigelman, President and CEO of TB Alliance, in the stakeholders' meeting covered by CNS (Citizen News Service).

The current TB treatment is too lengthy, too toxic and not effective enough in different programmatic settings. Hence there is an urgent need for better drug regimens. But perhaps a harder battle begins after getting a drug approved. Development plans for uptake of novel regimens must be implemented without avoidable delays and address usage that will have a meaningful impact.

Shobha Shukla, CNS (Citizen News Service)
(Shobha Shukla is the Managing Editor of CNS (Citizen News Service)